{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-011133","form_type":"8-K","ticker":"SFES","cik":"0000086115","company_name":"SAFEGUARD SCIENTIFICS INC","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.963226+00:00","generated_at":"2026-06-26T00:11:19.412499+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Safeguard Scientifics Q1 net loss $6.7M; strategic review with Houlihan Lokey continues","bullets":["Net loss $6.7M ($0.40 per share) vs net income $17.6M ($0.84 per share) in Q1 2021.","Repurchased 147,795 shares at avg $5.27 in Q1; additional $0.4M post-quarter at $4.71.","Funded $2.0M convertible loan to Prognos Health and $1.4M to Clutch Holdings.","Carrying value of ownership interests $24.1M vs cost $154.4M; Bright Health fair value $2.6M.","Strategic review with Houlihan Lokey ongoing; update expected by Q3 2022 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-011133","json":"https://secwatch.observer/filing/0001437749-22-011133.json","markdown":"https://secwatch.observer/filing/0001437749-22-011133.md","text":"https://secwatch.observer/filing/0001437749-22-011133.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/86115/000143774922011133/0001437749-22-011133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/86115/000143774922011133/sfe20220504_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:11:19.412499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}